Enzyme inhibitor may help lower cholesterol and unclog arteries

May 01, 2006

Atherosclerosis, the accumulation of cholesterol in the arteries that clogs the circulation and results in heart attacks and strokes, is a leading cause of death. One strategy for preventing heart disease and stroke is to clear out clogged arteries, restoring circulation. This process, known as reverse cholesterol transport is accomplished by the high-density lipoproteins (HDLs) in the blood. HDL transports excess cholesterol from the artery wall and macrophages and delivers it to the liver, where it is excreted as bile salts and cholesterol. In a study appearing in the May issue of the Journal of Clinical Investigation, Fumihiko Matsuura and colleagues from Columbia University, New York, reveal new features of this pathway that suggest an enzyme inhibitor currently in phase III clinical trials may help reduce cholesterol levels and atherosclerosis in humans.

One proposal for boosting reverse cholesterol transport has been to elevate plasma HDL levels by inhibiting a protein called CETP that transfers cholesterol esters from HDL to lower-density lipoproteins. However, there has been controversy in the medical literature as to whether CETP deficiency is pro- or anti-atherogenic. Matsuura and colleagues assessed the ability of HDL-2 from individuals deficient in CETP to promote cholesterol removal from macrophages. They observed a 2-3-fold increase in cholesterol efflux in these individuals compared to controls and they demonstrated that this was dependent on a molecule known as ABCG1, which is present on macrophages and contributes to the formation of HDL. They also found that the enhanced ability to promote cholesterol removal in these CETP-deficient individuals was due to increased amounts of the enzyme LCAT and apolipoprotein E in HDL-2, which allow the inner cholesterol ester-rich core of HDL-2 to expand to carry greater amounts of cholesterol. In an accompanying commentary, Robert Mahley and colleagues from the University of California, San Francisco, comment that as CETP does not appear to be essential for reverse cholesterol transport in humans, this raises the hope of using a CETP inhibitor to elevate HDL levels and therefore reduce the incidence of atherosclerosis.
-end-
TITLE: HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

AUTHOR CONTACT:
Fumihiko Matsuura
Osaka University, Osaka, Japan.
Phone: 81-6-6879-3732; Fax: 81-6-6879-3739; E-mail: fc-mastu@fb4.so-net.ne.jp

View the PDF of this article at: https://www.the-jci.org/article.php?id=27602

ACCOMPANYING COMMENTARY

TITLE: Putting cholesterol in its place: apoE and reverse cholesterol transport


AUTHOR CONTACT:
Robert W. Mahley
Gladstone Institute of Neurological Disease, San Francisco, California, USA.
Phone: (415) 734-2000; Fax: (415) 355-0820; E-mail: rmahley@gladstone.ucsf.edu

View the PDF of this article at: https://www.the-jci.org/article.php?id=28632

JCI Journals

Related Cholesterol Articles from Brightsurf:

Cholesterol's effects on cellular membranes
The findings have far-reaching implications in the general understanding of disease, the design of drug delivery methods, and many other biological applications that require specific assumptions about the role of cholesterol in cell membranes.

Autism-cholesterol link
Study identifies genetic link between cholesterol alterations and autism.

Microbes might manage your cholesterol
Researchers discover a link between human blood cholesterol levels and a gene in the microbiome that could one day help people manage their cholesterol through diet, probiotics, or entirely new types of treatment.

Experimental cholesterol-lowering drug effective at lowering bad cholesterol, study shows
Twice-yearly injections of an experimental cholesterol-lowering drug, inclisiran, were effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol, in patients already taking the maximum dose of statin drugs, according to data of the ORION-10 trial presented Saturday, Nov.

Rethinking how cholesterol is integrated into cells
Cholesterol is best known in connection with cardiovascular disease, but cholesterol is also vital for many fundamental processes in the body.

Seed oils are best for LDL cholesterol
Using a statistical technique called network meta-analysis, researchers have combined the results of dozens of studies of dietary oils to identify those with the best effect on patients' LDL cholesterol and other blood lipids.

Cholesterol leash: Key tethering protein found to transport cellular cholesterol
Cholesterol is an essential component of living organisms, but the mechanisms that transport cholesterol inside the cell are poorly understood.

New way to treat cholesterol may be on the horizon
A breakthrough discovery by scientists at Houston Methodist Research Institute could change the way we treat cholesterol.

How low should LDL cholesterol go?
New analysis shows that in a high-risk population, achieving ultra-low LDL cholesterol levels, down to <10 mg/dL, safely results in additional lowering of risk of cardiovascular events.

Does boosting 'good' cholesterol really improve your health?
A new review addresses the mysteries behind 'good' HDL cholesterol and why boosting its levels does not necessarily provide protection from cardiovascular risk for patients.

Read More: Cholesterol News and Cholesterol Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.